NexMed Confirms Nasdaq Hearing Date

October 20, 2009 9:00 AM EDT

EAST WINDSOR, N.J.--(BUSINESS WIRE)-- NexMed, Inc. (Nasdaq: NEXM), a developer of products based on the NexACT(R) technology, today announced that it has heard back from the Nasdaq Listing Qualifications Department regarding its request for a hearing concerning its possible delisting from the Nasdaq Capital Market, and that a hearing has been scheduled for Thursday, November 12, 2009. NexMed's stock will continue to trade on the Nasdaq Capital Market pending a final decision by Nasdaq, which typically occurs within four to five weeks after the completion of the formal hearing.

As announced on October 14, 2009, NexMed received a notice from Nasdaq indicating that it did not comply with the minimum $2.5 million stockholders' equity requirement for continued listing set forth in Marketplace Rule 5550(b). In the event that NexMed is unable to successfully appeal the delisting from Nasdaq Capital Market, NexMed's stock will be traded on the OTC Bulletin Board ("OTCBB").

As of June 30, 2009, the date of the most recently filed financial statements, the Company's total stockholders' equity was $1,700,553. In order to comply with the $2.5 million stockholders' equity criteria, the Company would need to increase its stockholders' equity through an equity financing and/or increased net income. The Company also remains on notice for maintaining the minimum $1 bid requirement as set forth in Marketplace Rule 5550(a)(2). However, because Nasdaq has temporarily suspended enforcement of this requirement, the Company now has until January 25, 2010 to meet that requirement.

About NexMed

NexMed's pipeline includes a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 alprostadil treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to, entering into licensing agreements for products under development, obtaining regulatory approval for its products under development, entering into a strategic transaction for the company, pursuing growth opportunities, and/or other factors, some of which are outside the control of the Company.

    Source: NexMed, Inc.

Related Categories

Press Releases

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?